Literature DB >> 31681406

EBV-miR-BART7-3p Imposes Stemness in Nasopharyngeal Carcinoma Cells by Suppressing SMAD7.

Longmei Cai1,2, Yufei Long1, Tuotuo Chong1, Wenzhi Cai1, Chi Man Tsang3, Xiaohan Zhou2, Yanling Lin2, Tengteng Ding1, Wenyan Zhou1, Hongli Zhao1, Yuxiang Chen1, Jianguo Wang1, Xiaoming Lyu1, William C Cho4, Xin Li1.   

Abstract

Cancer stem-like cells, possessing "stemness" properties, play crucial roles in progression, metastasis, and drug resistance in various cancers. Viral microRNAs (such as EBV-miR-BART7-3p), as exogenous regulators, have been discovered to regulate malignant progression of nasopharyngeal carcinoma (NPC), suggesting a possible role of viral microRNAs in imposing stemness. In this study, we found that EBV-miR-BART7-3p induce stemness of NPC cells. We firstly reported that EBV-miR-BART7-3p increased the percentage of side population cells, the development of tumor spheres, and the expression level of stemness markers in vitro. This viral microRNA also enhanced stem-like or cancer-initiating properties of NPC cells in vivo. Besides, we identified SMAD7 as a novel target gene of EBV-miR-BART7-3p in addition to PTEN gene we previously reported; this viral microRNA suppressed SMAD7, led to activation of TGF-β signaling, and eventually enhanced the stemness of NPC cells. Silencing of SMAD7 resembled the effects generated by EBV-miR-BART7-3p in NPC cells. After reconstitution of SMAD7, EBV-miR-BART7-3p-expressing cells underwent a phenotypic reversion. EBV-positive NPC cells were used to enable experimental validation. Finally, we further discovered that EBV-miR-BART7-3p increased chemo-resistance of NPC in vitro and in vivo, supporting that EBV-miR-BART7-3 resulted in increased stemness of NPC cells and lead to drug resistance and cancer recurrence. Overall, this study uncovered a novel mechanism underlying viral microRNA-associated stemness of NPC cells. This viral microRNA and its associated cellular genes may be potential therapeutic targets for restraining chemo-resistance and recurrence of NPC.
Copyright © 2019 Cai, Long, Chong, Cai, Tsang, Zhou, Lin, Ding, Zhou, Zhao, Chen, Wang, Lyu, Cho and Li.

Entities:  

Keywords:  EBV-miR-BART7-3p; Epstein-Barr virus; SMAD7; microRNA; nasopharyngeal carcinoma; stemness

Year:  2019        PMID: 31681406      PMCID: PMC6811651          DOI: 10.3389/fgene.2019.00939

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  41 in total

Review 1.  Negative regulation of TGF-beta receptor/Smad signal transduction.

Authors:  Susumu Itoh; Peter ten Dijke
Journal:  Curr Opin Cell Biol       Date:  2007-02-20       Impact factor: 8.382

2.  EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN.

Authors:  L-M Cai; X-M Lyu; W-R Luo; X-F Cui; Y-F Ye; C-C Yuan; Q-X Peng; D-H Wu; T-F Liu; E Wang; F-M Marincola; K-T Yao; W-Y Fang; H-B Cai; X Li
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

3.  Effect of tetrandrine on the TGF-β-induced smad signal transduction pathway in human hypertrophic scar fibroblasts in vitro.

Authors:  Lin Zunwen; Zhong Shizhen; Liu Dewu; Mao Yungui; Ning Pu
Journal:  Burns       Date:  2011-09-16       Impact factor: 2.744

4.  Inhibition of transforming growth factor beta signaling and Smad-dependent activation of transcription by the Latent Membrane Protein 1 of Epstein-Barr virus.

Authors:  Vassiliki Prokova; George Mosialos; Dimitris Kardassis
Journal:  J Biol Chem       Date:  2002-01-07       Impact factor: 5.157

Review 5.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Nat Rev Clin Oncol       Date:  2017-04-11       Impact factor: 66.675

Review 6.  Extracellular control of TGFbeta signalling in vascular development and disease.

Authors:  Peter ten Dijke; Helen M Arthur
Journal:  Nat Rev Mol Cell Biol       Date:  2007-11       Impact factor: 94.444

7.  MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells.

Authors:  Wen-Jun Wang; Si-Pei Wu; Jia-Bin Liu; Yong-Sheng Shi; Xue Huang; Qian-Bing Zhang; Kai-Tai Yao
Journal:  Cancer Res       Date:  2012-12-26       Impact factor: 12.701

Review 8.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962

9.  Role of the TGFβ/PDCD4/AP-1 Signaling Pathway in Nasopharyngeal Carcinoma and Its Relationship to Prognosis.

Authors:  Jie Ma; Shu-Hong Xuan; Yan Li; Zhi-Ping Zhang; Xin-Hua Li
Journal:  Cell Physiol Biochem       Date:  2017-10-11

10.  TGF-β Stimulates Endochondral Differentiation after Denervation.

Authors:  Ye Li; Austin Y Tian; Jennifer Ophene; Mason Y Tian; Zhenjiang Yao; Sidong Chen; Hongwei Li; Xiaoyan Sun; Hongyan Du
Journal:  Int J Med Sci       Date:  2017-04-08       Impact factor: 3.738

View more
  9 in total

1.  Prognostic Value of Oral Epstein-Barr Virus DNA Load in Locoregionally Advanced Nasopharyngeal Carcinoma.

Authors:  Yong-Qiao He; Ting Zhou; Da-Wei Yang; Yi-Jing Jia; Lei-Lei Yuan; Wen-Li Zhang; Tong-Min Wang; Ying Liao; Wen-Qiong Xue; Jiang-Bo Zhang; Xiao-Hui Zheng; Xi-Zhao Li; Pei-Fen Zhang; Shao-Dan Zhang; Ye-Zhu Hu; Fang Wang; William C Cho; Jun Ma; Ying Sun; Wei-Hua Jia
Journal:  Front Mol Biosci       Date:  2022-01-13

2.  CYLD Promotes Apoptosis of Nasopharyngeal Carcinoma Cells by Regulating NDRG1.

Authors:  Yanling Lin; Lingzhi Wang; Wenxiao Luo; Xiaohan Zhou; Yuting Chen; Kaifan Yang; Jinrong Liao; Dehua Wu; Longmei Cai
Journal:  Cancer Manag Res       Date:  2020-10-27       Impact factor: 3.989

Review 3.  Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.

Authors:  Ya Cao; Longlong Xie; Feng Shi; Min Tang; Yueshuo Li; Jianmin Hu; Lin Zhao; Luqing Zhao; Xinfang Yu; Xiangjian Luo; Weihua Liao; Ann M Bode
Journal:  Signal Transduct Target Ther       Date:  2021-01-12

4.  Epstein-Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7.

Authors:  Wei-Jie Luo; Shi-Wei He; Wen-Qing Zou; Yin Zhao; Qing-Mei He; Xiao-Jing Yang; Rui Guo; Yan-Ping Mao
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-23

Review 5.  Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer.

Authors:  Valli De Re; Laura Caggiari; Mariangela De Zorzi; Valentina Fanotto; Gianmaria Miolo; Fabio Puglisi; Renato Cannizzaro; Vincenzo Canzonieri; Agostino Steffan; Piero Farruggia; Egesta Lopci; Emanuele S G d'Amore; Roberta Burnelli; Lara Mussolin; Maurizio Mascarin
Journal:  Infect Agent Cancer       Date:  2020-06-23       Impact factor: 2.965

Review 6.  MiRNAs in Radiotherapy Resistance of Nasopharyngeal Carcinoma.

Authors:  Yutong Tian; Lu Tang; Pin Yi; Qing Pan; Yaqian Han; Yingrui Shi; Shan Rao; Shiming Tan; Longzheng Xia; Jinguan Lin; Linda Oyang; Yanyan Tang; Jiaxin Liang; Xia Luo; Qianjin Liao; Hui Wang; Yujuan Zhou
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

7.  Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma.

Authors:  Yanling Lin; Xiaohan Zhou; Kaifan Yang; Yuting Chen; Lingzhi Wang; Wenxiao Luo; Yujiang Li; Jinrong Liao; Yingtong Zhou; Yiming Lei; Yanting Zhang; Dehua Wu; Longmei Cai
Journal:  Oncogene       Date:  2021-04-06       Impact factor: 9.867

Review 8.  The World of Oral Cancer and Its Risk Factors Viewed from the Aspect of MicroRNA Expression Patterns.

Authors:  Ovidiu Aghiorghiesei; Oana Zanoaga; Andreea Nutu; Cornelia Braicu; Radu Septimiu Campian; Ondine Lucaciu; Ioana Berindan Neagoe
Journal:  Genes (Basel)       Date:  2022-03-26       Impact factor: 4.141

9.  Aberrant miR-362-3p is Associated with EBV-Infection and Prognosis in Nasopharyngeal Carcinoma and Involved in Tumor Progression by Targeting JMJD2A.

Authors:  Xiangyun Wang; Ping Chen
Journal:  Onco Targets Ther       Date:  2022-01-28       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.